SCHEMBL10183727

SCHEMBL10183727

CCC(=O)Nc1cccc(N(C(=O)Cc2cccs2)C2C(=O)N(C3CCCCC3)c3ccccc32)c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ HPGD P15428 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ MEN1 O00255 4/20 0.38
▸ KMT2A Q03164 4/20 0.38
▸ POLB P06746 2/20 0.38
▸ ESR1 P03372 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ CCKBR P32239 7/20 0.37
▸ CCKAR P32238 5/20 0.37
▸ LMNA P02545 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ OPRM1 P35372 2/20 0.36
▸ OPRK1 P41145 2/20 0.36
▸ OPRL1 P41146 1/20 0.36
▸ OPRD1 P41143 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10184154 0.87 POLB (0.39) ALDH1A1HSD17B10MEN1KMT2APOLB
SCHEMBL10185945 0.86 OPRM1 (0.39) ALDH1A1POLBCCKBRCCKAROPRM1
SCHEMBL10185926 0.85 OPRM1 (0.39) ALDH1A1POLBHTTLMNAMAPT
SCHEMBL10183666 0.85 OPRM1 (0.39) ALDH1A1POLBHTTLMNAMAPT
SCHEMBL10184153 0.85 OPRM1 (0.39) HPGDPOLBOPRM1OPRK1OPRL1
SCHEMBL10185544 0.82 OPRM1 (0.40) ALDH1A1POLBLMNAMAPTOPRM1
SCHEMBL10185925 0.81 MEN1 (0.39) ALDH1A1HSD17B10MEN1KMT2APOLB
SCHEMBL10183731 0.81 USP2 (0.39) ALDH1A1HSD17B10HPGDKDM4EMEN1
SCHEMBL10185950 0.81 SMN1; SMN2 (0.39) ALDH1A1HSD17B10HPGDKDM4EMEN1
SCHEMBL10183972 0.80 OPRM1 (0.36) ALDH1A1HPGDMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012009678-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE AGIOS PHARMACEUTICALS, INC. (US) 2012-01-19 — — WO disclosed
Send feedback